About

Perspective Therapeutics, Inc., is a clinical stage, radiopharmaceutical development company that is pioneering advanced treatments for cancers. The Company’s proprietary technology utilizes the alpha emitting isotope, Pb-212, to deliver powerful radiation specifically to cancer cells via targeting peptides. Complementarily, the Company is developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization and treatment of specific tumors, which has the potential to improve efficacy and minimize toxicity associated with many other types of cancer treatments.